AstraZeneca (AZN.L,AZN) said Ultomiris has been approved in the United States as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. The FDA approval was based on positive results from the CHAMPION-NMOSD Phase III trial.
NMOSD is a rare and debilitating autoimmune disease that affects the central nervous system, including the spine and optic nerves.
Ultomiris is also approved for certain adults with NMOSD in Japan and the European Union. The company said regulatory reviews are ongoing in additional countries.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.